Key regions: Australia, Japan, United States, Germany, Europe
The demand for Anti-Coagulants in ASEAN has been steadily increasing in recent years due to various factors.
Customer preferences: Patients are increasingly opting for Anti-Coagulants as a preventive measure against blood clots and stroke. The rising prevalence of lifestyle diseases such as obesity, diabetes, and hypertension have also contributed to the growth of the market. Additionally, the aging population in ASEAN countries has led to an increase in the number of patients suffering from cardiovascular diseases and other chronic conditions that require Anti-Coagulants.
Trends in the market: Indonesia, Thailand, and Malaysia are the largest markets for Anti-Coagulants in ASEAN. However, Vietnam and the Philippines are expected to witness significant growth in the coming years due to an increase in healthcare spending and improved access to healthcare facilities. The market is dominated by oral Anti-Coagulants, which are preferred by patients due to their ease of administration and lower risk of side effects compared to injectable Anti-Coagulants. However, injectable Anti-Coagulants are still widely used in hospitals for patients who require immediate treatment.
Local special circumstances: The regulatory environment in ASEAN countries can be challenging for foreign companies looking to enter the market. Each country has its own set of regulations and requirements for importing and selling pharmaceutical products. In addition, the lack of harmonization between regulatory bodies in ASEAN can make it difficult for companies to navigate the market. Local partnerships and joint ventures can be an effective way for foreign companies to gain a foothold in the market.
Underlying macroeconomic factors: The growing middle class in ASEAN countries has led to an increase in healthcare spending and a greater demand for high-quality medical products. Additionally, the rise of medical tourism in the region has contributed to the growth of the Anti-Coagulants market. Patients from neighboring countries are increasingly traveling to ASEAN countries for medical treatment, which has created new opportunities for pharmaceutical companies. However, the COVID-19 pandemic has had a significant impact on the healthcare industry in ASEAN, with many countries diverting resources to combat the virus. The long-term impact of the pandemic on the Anti-Coagulants market remains to be seen.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
